(818) 356-8232 info@theacrm.com


Below is a sample of existing clinical evidence:
“Allogeneic UC MSCs (umbilical cord mesenchymal stem cells) were infused intravenously on days 0 and 7… no transplantation-related adverse events were observed. 32.5% patients achieved MCR (major clinical response), 27.5% patients achieved PCR (partial clinical response) during 12 months of follow up.”

– “Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study,” Wang et al, Arthritis Research & Therapy, 2014

For further information regarding regenerative medicine, please refer to information provided by American Academy of Integrative Cell Therapy (AAICT).